Sandoz Group AG Website

Sandoz Group AG

SWX-SDZ

Company Overview

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.

  • Name

    Sandoz Group AG

  • CEO

    Richard Saynor

  • Website

    www.sandoz.com

  • Sector

    Pharmaceuticals

  • Year Founded

    1886

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • With autonomy from its former parent, we think Sandoz can freely allocate resources to fit its best needs and grow the business.

  • Sandoz is one of the largest biosimilars players in the world, and we believe it is well-positioned to benefit from the fast pace of growth expected in the market over the next decade, thanks to increasing biosimilars uptake and upcoming patent cliffs.

  • Sandoz has a deep pipeline of biosimilars and complex injectables, and achieving success in these markets and generating a bigger portion of sales from these products will boost margins.

Bears Say

  • Off-patent drugs face low- to mid-single-digit price erosion year over year, and regulatory actions and competition in the drug supply chain could increase headwinds.

  • Sandoz lags large pharmaceutical firms in terms of pipeline depth and resources, which could hurt its positioning in the biosimilar market.

  • Sandoz could face costly litigation battles with larger healthcare firms whenever it submits applications to launch its version of expiring reference drugs.

Source: Morningstar Analysis - Oct 30, 2025
SWX:SDZ